African Journal of Infectious Diseases Research

ISSN 2756-3340

African Journal of Infectious Diseases Research | Vol. 12, No. 8, August 2025 | pp. 593–599

DOI: 10.46882/AJIDR/148848

Article Type: Epidemiological Study

Title: Seroprevalence, risk factors, and hepatic fibrosis staging of chronic hepatitis C virus infection among people who inject drugs

Names of Authors: Karim El-Sayed¹*, Sofie Van Dijk²

Authors’ Affiliations: ¹Department of Tropical Medicine and Hygiene, Alexandria University, Alexandria, Egypt. ²Department of Infectious Diseases, Amsterdam University Medical Centers, Amsterdam, Netherlands.

Abstract: People who inject drugs bear a disproportionate burden of hepatitis C virus transmission and progressive liver disease. We evaluated anti-HCV seroprevalence, active viremia, and non-invasive liver fibrosis scores among individuals attending harm reduction centers. Blood samples from 335 participants were screened via chemiluminescent immunoassay, quantitative HCV RNA polymerase chain reaction, and transient elastography. Anti-HCV seropositivity was 44.8 percent, with active viremia confirmed in 72.0 percent of seropositive individuals and advanced fibrosis present in 23.1 percent. Needle sharing and incarceration history independently predicted infection. Expanding community-based pan-genotypic direct-acting antiviral therapy and needle exchange programs is vital.

Keywords: Hepatitis C virus, People who inject drugs, Direct-acting antivirals, Liver fibrosis, Harm reduction

Citation: El-Sayed K, Van Dijk S (2025). Seroprevalence, risk factors, and hepatic fibrosis staging of chronic hepatitis C virus infection among people who inject drugs. African Journal of Infectious Diseases Research, 12(8): 593–599. DOI: 10.46882/AJIDR/148848

Manuscript Timeline: Received: July 05, 2025; Revised: August 05, 2025; Accepted: August 17, 2025; Published: August 25, 2025